Hemab Therapeutics Holdings, Inc.

424B4 priced

Price $18.00 · 16,750,000 shares · Gross proceeds $301,500,000

Hemab Therapeutics Holdings, Inc. is conducting an initial public offering (IPO) of 16,750,000 shares of common stock at $18.00 per share, with proceeds totaling $280.395 million. The company, a clinical-stage biotechnology firm, focuses on developing therapies for blood coagulation disorders, with two lead candidates in Phase 1/2 and Phase 2 trials. The IPO follows a corporate reorganization, and the stock will list on Nasdaq under the symbol 'COAG'. The offering includes underwriters such as Goldman Sachs, Jefferies, and Wedbush PacGrow.

EFFECT effective

Hemab Therapeutics Holdings, Inc. has received effectiveness for its S-1 registration statement, indicating the company is proceeding with its initial public offering (IPO). The filing suggests the company is seeking to raise capital, likely for advancing its hematology-focused therapeutic pipeline, though specific details about the offering's size, use of proceeds, or business operations are not provided in the visible text.

CERT inactive

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for blood coagulation disorders. The company's lead candidate, sutacimig (HMB-001), is in Phase 1/2 trials for Glanzmann thrombasthenia and Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The IPO aims to raise capital to advance its pipeline and expand commercialization efforts.

S-1/A amended

Price $17.00 · Range $16.00 to $18.00 · 15,000,000 shares · Gross proceeds $270,000,000

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for blood coagulation disorders. The company is conducting an IPO of 15 million common stock shares, with an estimated price range of $16.00 to $18.00 per share. Its lead asset, sutacimig (HMB-001), is in Phase 1/2 trials for Glanzmann thrombasthenia and Phase 2 trials for Factor VII deficiency, while HMB-002 is in Phase 1/2 trials for Von Willebrand Disease. The company aims to advance multiple clinical programs under its 'Hemab 2x3 by 2030' roadmap but faces risks related to early-stage development and regulatory approvals.

S-1/A amended

Hemab Therapeutics Holdings, Inc. filed an S-1/A amendment to its registration statement, focusing on details of its upcoming IPO. The filing includes information on offering expenses, indemnification of directors and officers, recent unregistered securities sales, and corporate reorganization details. The company, engaged in hematology-focused therapeutic development, aims to raise capital through this offering.

8-A12B effective

Hemab Therapeutics Holdings, Inc. is registering its common stock for listing on The Nasdaq Stock Market LLC under Form 8-A12B, referencing the previously filed S-1/A registration statement. The filing incorporates by reference the prospectus details from the S-1/A, including the company's clinical-stage biotechnology focus on coagulation disorder therapies and its initial public offering (IPO) details. The current filing emphasizes the registration of securities under Section 12(b) of the Securities Exchange Act of 1934.

S-1/A amended

Price $17.00 · Range $16.00 to $18.00 · 11,764,706 shares

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for blood coagulation disorders. The company is conducting Phase 1/2 and Phase 2 trials for its lead asset, sutacimig (HMB-001), targeting Glanzmann thrombasthenia and Factor VII deficiency, and a Phase 1/2 trial for HMB-002 for Von Willebrand Disease. The IPO aims to raise capital to advance its pipeline, with an estimated offering price of $16.00-$18.00 per share. The company is an emerging growth company with a strategic roadmap to expand its coagulation franchise by 2030.

S-1 filed

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for blood coagulation disorders. The company is conducting an initial public offering (IPO) of its common stock, with shares to be listed on the Nasdaq Global Select Market under the symbol 'COAG.' Hemab's lead candidates, sutacimig (HMB-001) and HMB-002, are in Phase 1/2 and Phase 2 clinical trials for rare bleeding disorders, with plans to advance to Phase 3 trials. The company aims to establish a coagulation franchise through its 'Hemab 2x3 by 2030' strategy, targeting 2 commercial medicines, 2 late-stage programs, and 2 early-stage programs by 2030.

DRS/A amended

Hemab Therapeutics Holdings, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its clinical-stage biotechnology programs focused on blood coagulation disorders. The company's lead asset, sutacimig (HMB-001), is in Phase 1/2 trials for Glanzmann thrombasthenia and Phase 2 trials for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The filing outlines a strategic roadmap to build a coagulation franchise with 2 commercial medicines and multiple clinical programs by 2030. The IPO is contingent on Nasdaq listing and includes underwriters such as Goldman Sachs and Jefferies.

DRS filed

Hemab Therapeutics Holdings, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its late-stage biotechnology pipeline focused on blood coagulation disorders. The company is developing two lead assets, sutacimig (HMB-001) and HMB-002, in clinical trials for rare bleeding conditions. The IPO is contingent on Nasdaq listing approval, and the company is classified as an emerging growth company with reduced reporting requirements.